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Abstract
Background: Clinical experience and animal studies have suggested that positron emission tomography (PET) using
fluorine-18-labeled fluorodeoxyglucose (18F-FDG) may be promising for imaging of bone infections. In this study, we
aimed to establish the accuracy of 18F-FDG PET scanning for monitoring the response to poly(lactide-co-glycolide)
(PLGA) vancomycin beads for treatment of bone infection.
Methods: PLGA was mixed with vancomycin and hot-compress molded to form antibiotic beads. In vitro, elution
assays and bacterial inhibition tests were employed to characterize the released antibiotics. In vivo, cylindrical cavities
were made in six adult male New Zealand white rabbits, and Staphylococcus aureus or saline was injected into the
cavity to create a bone infection. After 2 weeks, the infection was confirmed by bacterial cultures, and the defect was
filled with PLGA vancomycin beads. The treatment response was monitored by 18F-FDG PET.
Results: The biodegradable beads released high concentrations of vancomycin (well above the breakpoint sensitivity
concentration) for treatment of bone infection. In bacterial inhibition tests, the diameter of the sample inhibition zone
ranged from 6.5 to 10 mm, which was equivalent to 12.5–100 % relative activity. 18F-FDG PET results showed that
uncomplicated bone healing was associated with a temporary increase in 18F-FDG uptake at 2 weeks, with return to
near baseline at 6 weeks. In the infected animals, localized infection resulted in intense continuous uptake of 18F-FDG,
which was higher than that in uncomplicated healing bones. Bone infection was confirmed with positive bacterial
cultures. In vancomycin-treated animals, data showed rapidly decreasing amounts of 18F-FDG uptake after treatment.
Conclusions: In vitro and in vivo analyses showed that the use of biodegradable PLGA vancomycin beads successfully
eradicated S. aureus infection in damaged bone.
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Background
Despite advances in surgical techniques and the avail-
ability of newly developed antibiotics, bone infections
after surgical procedures and trauma continue to be a
difficult problem for surgeons [1, 2]. Typically, operative
debridement and antibiotic therapy are preferred treat-
ments for bone infection [3]. Although intravenous route
of antibiotic injection produces adequate antibiotic con-
centration in the blood, recurrence of infection, the high
cost of the antibiotics, and poor patient compliance are
still problems. Osseous defects after debridement can be
reconstructed using various techniques, such as cancel-
lous bone grafting, free microvascular bone transfer, and
distraction osteogenesis [1, 4]. However, substantial mor-
bidity is associated with harvesting of bone grafts and
bone transplantation. Currently, the standard treatment
remains a combination of surgical intervention and ad-
ministration of an effective local antibiotic therapy [1, 5].
For antibiotic treatment, incorporation of antibiotics
into polymethyl methacrylate (PMMA) [6, 7], a concept
that was originally developed by Buchholz et al., is com-
monly used [8]. Antibiotic-impregnated PMMA beads
provide a high local concentration of the drug and have
advantages over intravenous injection in that the beads
yield fewer systemic complications and allergic reactions.
However, PMMA beads require a second operation for
removal after prolonged implantation [1, 9].
Various types of carrier materials have been used based
on their ability to achieve sustained bactericidal concen-
trations of the antibiotic [3, 10–13]. A biodegradable car-
rier as a slow release system for delivering antibiotics may
be better than PMMA beads and intravenous antibiotics
in several ways. First, biodegradable beads provide long-
term administration of a bactericidal concentration of the
antibiotic, and the biodegradability of the beads can be
varied to treat many types of infections. Second, be-
cause the biodegradable beads dissolve, there is no need
for surgical removal and soft tissue reconstruction.
Poly(lactide-co-glycolide) (PLGA) copolymer is a prom-
ising biodegradable material that is nontoxic, elicits a
minimal inflammatory response, and can be absorbed
with no accumulation in vital organs. Garvin et al.
described the use of polyglycolide beads loaded with
gentamicin for effective treatment of tibial Staphylococ-
cus aureus osteomyelitis in a canine model [14]. Ueng
et al. developed a hot-compress molded method to
manufacture PLGA copolymer antibiotic beads and
achieved sustained in vitro antibiotic release for more
than 30 days [11, 12]. In addition, Ueng et al. showed
in vivo antibiotic release for 56 days from PLGA
copolymer antibiotic beads in a rabbit model [15].
However, the efficacy of PLGA vancomycin beads for
treatment of experimental bone infection due to S.
aureus has never been reported.
Fluorine-18-fluoro-2-deoxy-D-glucose positron emis-
sion tomography combined with computed tomography
(18F-FDG PET/CT) is a cutting-edge functional imaging
method that provides images with higher resolution and
concomitant anatomical information. 18F-FDG PET/CT
has been used as a diagnostic imaging modality for de-
tection of prosthetic joint infection [16, 17], Alzheimer’s
disease [18], inflammatory and infectious vascular dis-
ease [19], and tumors [20]. Postsurgical infection is one
of the most prevalent and challenging complications
faced by orthopedic surgeons and patients, and clinical
experience suggests that 18F-FDG PET/CT may be
promising for imaging of bone infections [21–24]. Pre-
vious animal studies have shown that 18F-FDG uptake is
increased in the context of bacterial infections [25–29].
18F-FDG uptake is also significantly higher in the osteo-
myelitic region than in healing bone [28].
In the present study, we evaluated the release of
vancomycin from PLGA vancomycin beads and exam-
ined the relative activity of the released antibiotics in
vitro. In addition, we examined the use of 18F-FDG PET/
CT for quantitative monitoring of the response to PLGA
vancomycin bead treatment in a model of bone
infection.
Methods
Development of a biodegradable bead for antibiotics
A biodegradable antibiotic bead was developed using
PLGA copolymer and vancomycin (Abbott Laboratories,
North Chicago, IL, USA). The PLGA copolymers used
were poly(D,L)-lactide-co-glycolide with a ratio of 50:50
and an intrinsic viscosity of 0.4 (Boehringer Ingelheim
KG, Germany). All copolymers were available in powder
form with particle size ranges from 100 to 200 mm. The
copolymer and vancomycin were premixed using a dry
mixer (copolymer to vancomycin ratio of 5:1). The mix-
ture was molded into 5-mm diameter beads by a com-
pression molding machine at 55 ° C [12, 15].
In vitro elution assay
An in vitro elution method was employed to determine
the release characteristics of antibiotics from the beads.
A phosphate-buffered saline (PBS, pH 7.4) was used as
the dissolution medium. The beads were placed in glass
test tubes with a volume of 1 mL PBS. All tubes were in-
cubated at 37 °C. The dissolution medium was collected
and analyzed at every 24-h interval. Fresh PBS (1 mL)
was then added for the next 24-h period, and this pro-
cedure was repeated until the capsule was fully dis-
solved. The antibiotic concentrations in buffer for the
elution studies were determined by a high-performance
liquid chromatography (HPLC) assay standard curve for
vancomycin. The HPLC analyses were conducted on a
Walters 600 Multi-solvent Delivery System. The column
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used for separation of the antibiotics was a SYMMETRY
C8, 3.9 cm × 150 mm HPLC column (Waters). The mobile
phase contained 0.01 mol heptanesulphonic acid (Fisher
Scientific UK Ltd.) and acetonitrile (Mallinckrodt, USA)
(85/15, v/v). The absorbency was monitored at 280 nm,
and the flow rate was 1.4 mL/min. All samples were
assayed in triplicate, and sample dilutions were per-
formed to bring the unknown concentrations into the
range of the assay standard curve. A calibration curve
was made for each set of the measurements (correl-
ation coefficient >0.99).
Activities of antibiotics
The minimum inhibitory concentration (MIC) of
vancomycin to S. aureus (ATCC 259523) was deter-
mined using an antibiotic tube dilution method in
Cation Supplemented Mueller-Hinton Broth (Difco
Laboratories, Detroit, MI). Vancomycin was diluted
serially twofold in tubes containing 0.5 mL of the
cation-supplemented Mueller-Hinton broth. The S.
aureus inocula for each series of tubes was 0.5 mL of
an overnight culture containing 5.0 × 105 colony-
forming units/mL. The MIC was considered to be the
lowest concentration of antibiotic that prevented tur-
bidity after 24 h of incubation at 37 °C. The antibiotic
concentrations at the transition point between bacterial
killing and resistance to the antibiotic (the breakpoint
sensitivity limit) for vancomycin were determined by
tube dilution sensitivities.
The relative activity test of vancomycin to S. aureus
(ATCC65389) was determined using an antibiotic disk
diffusion method in Nutrient Broth (beef extract, pep-
tone, Difco Laboratories). The eluent of the capsules
was tested up to 36 days. Each sample was first di-
luted or concentrated to 50 mg/mL. Eight microliters
of the buffer sample from each daily buffer sample
was pipetted onto 6-mm absorption disks. The disks
were placed on the nutrient agar plates that were
seeded with a layer of S. aureus, and the zones of in-
hibition were measured with a micrometer after 16–
18 h of incubation at 35 °C. The equation and other
relevant items for relative activity were as follows:
relative activity (%) = (the diameter of sample inhib-
ition zone − the diameter of disk)/(the diameter of
maximum inhibition zone − the diameter of disk).
Animal model of bone defect
Six adult male New Zealand white rabbits weighing 2.5–
3.4 kg were used. All animal procedures were reviewed
and approved by the Institutional Animal Care and Use
Committee of the Chang Gung Memorial Hospital. The
methods were carried out in accordance with the
approved guidelines.
Induction of infection (first stage of surgery)
A cylindrical bony cavity (15 mm × 12 mm × 10 mm)
was surgically made using a round bur and obliterated
with a customized PMMA spacer at the left and right
distal femur of each rabbit. The bone cement acted as a
foreign body to conduct infection. Subsequently, 0.1 mL
of 1 × 105 colony-forming units/mL of S. aureus was
withdrawn by a pipette tip and directly applied to the
space surrounding the bone cement (three rabbits), and
0.1 mL of sterile saline was applied to the corresponding
space of control group (three rabbits). The periosteal
and fascial layers were closed over the cortical defect.
Debridement (second stage of surgery)
Two weeks after the initial surgery, all animals under-
went the second stage of surgery. Using the previous
surgical approach, the defect area was exposed and swab
cultures were taken to confirm that the induction of
staphylococcal bone infection had been successful. The
biodegradable PLGA vancomycin beads were implanted
into the cavities for infection therapy. The swab speci-
mens were cultured for 20 h at 35 °C in blood agar
plates. The bone cement was removed and separately
cultured for 4 days at 35 °C on brain heart infusion solu-
tion (BBL; Becton Dickinson).
18F-FDG PET/CT
18F-FDG PET was performed for each animal at 2 weeks
after the second stage of surgery. A mean of 96 MBq of
18F-FDG (range, 89–100 MBq) was injected into the ear
artery. The animals were not fasted before 18F-FDG
administration. PET/CT scanning was performed 40 min
after the injection of 18 F-FDG with the GE DSTE PET/
CT scanner that was equipped with a three-dimensional
(3D) mode image acquisition system. The PET acquires
47 contiguous slices with an axial field of view of 70 cm.
The slice thickness of the scanner is 3.75 mm, and the
spatial resolution was 6 mm in full width at half max-
imum in the center of the field of view. The CT was per-
formed using a 16-slice helical CT. The CT scan data
were collected at an auto mAs and 120 kV. After the
CT scan, an emission scan was obtained from knee at
a rate of 3 min per bed. Attenuation-corrected PET
images using the CT data were reconstructed using
an ordered subset expected maximization algorithm
(20 subsets, 2 iterations).
PET data analysis
Quantitative analysis was performed on the circular re-
gions of interest (ROIs) area of the right and left distal
femur. 18F-FDG accumulation was reported as the stan-
dardized uptake value (SUV), which was calculated as
the radioactivity of the ROI divided by the relative
injected dose, expressed per kilogram of body weight.
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Results
Development of biodegradable vancomycin beads
The PLGA vancomycin mixture was hot-compressed
into a vancomycin bead of 5-mm diameters, as shown
schematically in Fig. 1.
In vitro elution assay
The release curves of vancomycin from the PLGA beads
are shown in Fig. 2. Three samples were performed for
each test. The mean vancomycin concentrations on days
1, 2, 5, 10, 15, 20, 25, 30, and 35 from the beads were
724.4, 331.1, 128.8, 21.9, 11.5, 17.8, 11.5, 6.6, and
7.1 mg/L, respectively. Gradual release of vancomycin
was observed from the biodegradable beads over the en-
tire 40 days, remaining above the breakpoint sensitivity
level through day 36. However, vancomycin release was
the most obvious during the first 48 h. The MIC and
breakpoint sensitivity of vancomycin for S. aureus were
1.01 and 5 mg/L, respectively.
Relative activity test of eluted vancomycin
The resulting values for relative activity and the diam-
eter of the inhibition zone for beads are shown in Fig. 3.
Each point represents three samples. The diameters of
the sample inhibition zones ranged from 6.5 to 10 mm,
and the relative activity ranged from 12.5 to 100 %.
Confirmation of staphylococcal infection and vancomycin
treatment
In the infected animals, bone infection was confirmed
with positive bacterial cultures during the debridement
(Fig. 4a–c), and the defect was filled with a PLGA vanco-
mycin bead (Fig. 4d). In the control group, none of the
corresponding cultures were positive.
18F-FDG PET/CT imaging
Coronal (Fig. 5a), transaxial (Fig. 5b), and sagittal (Fig. 5c)
18F-FDG PET/CT images were acquired. 18F-FDG PET
Fig. 1 Development of biodegradable vancomycin beads. The PLGA
vancomycin mixture was hot-compressed into a vancomycin bead
of 5 mm in diameter
Fig. 2 Release curves of biodegradable vancomycin beads. Each
point represents three samples. The MIC and breakpoint sensitivity of
vancomycin for S. aureus were 1.01 and 5 mg/L
Fig. 3 Results of relative activity and the diameter of the inhibition
zone. Each point represents three samples. The diameters of the
sample inhibition zones ranged from 6.5 to 10 mm and the relative
activity ranged from 12.5 to 100 %
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Fig. 4 Confirmation of staphylococcal infection and vancomycin treatment. In the infected animals, bone infection was confirmed with positive
bacterial cultures during the debridement (a–c) and the defect was filled with a PLGA vancomycin bead (d)
Fig. 5 18F-FDG PET/CT imaging. Coronal (a), transaxial (b), and sagittal (c) 18F-FDG PET/CT images. (d) PET image for quantitative analysis
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image for quantitative analysis is shown in Fig. 5d. There
were significant differences in 18F-FDG uptake between the
experimental and control groups. Two weeks after the ini-
tial surgery, localized infection resulted in an intense con-
tinuous uptake of 18F-FDG (Fig. 6b, d), which was higher
than that of the healing bones in the control group (Fig. 6a,
c). Compared with the initial deep infection (Fig. 7a, c),
PET images showed rapidly decreasing amounts of 18F-
FDG intensity after 2 weeks of vancomycin beads treatment
in the infected bone regions (Fig. 7b, d). In the mean SUV
results, the infection group showed a significantly higher
mean SUV than the control group (control group vs. infec-
tion group: 1.56 ± 0.17 vs. 2.58 ± 0.36, p < 0.01, n = 6;
Fig. 8a). The use of biodegradable PLGA vancomycin beads
was successful for eradication of the S. aureus pathogen
from bone (pretreatment vs. posttreatment: 2.58 ± 0.36 vs.
1.67 ± 0.30, p < 0.01, n = 6; Fig. 8b).
Discussion
In the present study, in vitro data showed that the
biodegradable beads released high concentrations of
vancomycin during the time needed to treat bone in-
fection. The diameter of the sample inhibition zone
ranged from 6.5 to 10 mm, which was equivalent to
12.5–100 % relative activity in the bacterial inhibition
test. In vivo results showed that localized infection
resulted in intense continuous uptake of 18F-FDG,
which was higher than that in uncomplicated healing
bones. Bone infection was confirmed with positive
bacterial cultures. In the vancomycin-treated animals,
data showed rapidly decreasing amounts of 18F-FDG
uptake after treatment.
Bacterial infections in surgery can be devastating and
are often associated with considerable morbidity and poor
functional outcomes [30]. The management of postopera-
tive infection requires surgical debridement, the removal
of all necrotic tissue and implants, and the administration
of systemic antibiotics. Nevertheless, antibiotic treatment
may be inadequate or ineffective in patients with poorly
vascularized infected tissues [31]. Delivering local antibi-
otics by using antibiotic-impregnated biodegradable car-
riers has been proposed to provide a sustained release of
Fig. 6 18F-FDG PET/CT images in the control (a, c) and infection groups (b, d). Localized infection resulted in an intense continuous uptake of
18F-FDG (b, d) which was higher than that of healing bones in control group (a, c)
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antibiotics to infected areas, replacing intravenous antibi-
otics infusion. The possibility of PLGA copolymer being a
biodegradable antibiotic carrier has been studied for years.
In most previous studies, the antibiotic was microencap-
sulated in a PLGA bead with a high molecular weight
(molecular weight 3.26 × 104 Da), a high percentage of the
poly(lactic acid) ratio (70:30), a high antibiotic loading
dosage (50 %), and a high formation temperature (110 °C)
[32–35]. The present study used a hot-compress molded
method with a low molecular weight (molecular weight
5000 Da vs. 3.26 × 104 Da), a low ratio of poly(lactic acid)
ratio copolymer (50:50 vs. 70:30), a low antibiotic loading
dosage (16.6 vs. 50 %), and a low formation temperature
(55 vs. 110 °C) to form a biodegradable antibiotic bead de-
livery system. In this study, the authors achieved
36 days of a sustained release of antibiotic from this
antibiotic delivery system in vitro (Figs. 2 and 3)
which is adequate for treatment of posttraumatic
osteomyelitis (3–6 weeks) [3, 32].
Based on our in vitro results, we next monitored the
treatment response of PLGA vancomycin beads in the
infection regions in vivo. 18F-FDG, the most commonly
used PET tracer for diagnosis of infection [36], has been
shown to localize autoradiographically in the regions
with the highest numbers of macrophages and leuko-
cytes [26]. The use of 18F-FDG PET to image bacterial
Fig. 7 18F-FDG PET/CT images in the infection (a, c) and vancomycin-treated groups (b, d). Compare to the initial deep infection (a, c), PET
images showed rapidly decreasing amounts of 18F-FDG intensity after 2 weeks of vancomycin beads treatment in infected bone regions (b, d)
Fig. 8 Quantitative analysis of PET image. a The infection group
showed a significantly higher mean SUV than that of the control
group (p < 0.01). (b) Mean SUV data showed a significantly lower
value after vancomycin beads treatment (p < 0.01). Op operation,
Inf infection, Vanco vancomycin
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infections is based on the intensive use of glucose by mac-
rophages and leukocytes [26]. Fluoro-D-deoxyglucose is
transported into cells via glucose transporters and phos-
phorylated by hexokinase to 18F-2′-FDG-6 phosphate but
is not metabolized. The degree of cellular FDG uptake is
related to the cellular metabolic rate and to the number of
glucose transporters [37]. In activated cells, such as neu-
trophils, lymphocytes, monocytes, and macrophages, both
the number and expression of glucose transporters are
increased, and the affinity of deoxyglucose for these trans-
porters is also increased [38–40]. Although the early
stages of bone healing, involving an inflammatory phase
with a highly activated state of cell metabolism and glu-
cose consumption may mimic infection on PET images
[41, 42]. However, the localized infection resulted in an
intense continuous uptake of 18F-FDG (Fig. 6b, d), which
was higher than that of the healing bones in the inflamma-
tory phase (Fig. 6a, c) in this study. Our results consist
with previous study demonstrating that bone infection
could be distinguished from bone healing by 18F-FDG
PET analysis [28].
Previous studies have shown that localized infection by
S. aureus pathogen resulted in an intense continuous
uptake of 18F-FDG over 3 weeks in an untreated-
infection group [28, 43]. In the present study, PET im-
ages showed decreasing amounts of 18F-FDG intensity in
infected bone regions after bead treatment for 2 weeks
(Fig. 7b, d). The mean SUV data also showed a signifi-
cantly lower value after bead treatment (Fig. 8). Thus,
our results showed that the use of biodegradable PLGA
vancomycin beads was successful for eradication of the
S. aureus pathogen from bone.
The rabbit model of S. aureus osteomyelitis has been
used to explore the diagnostic efficacy of 18F-FDG PET
scan. Lankier et al. showed that foreign-body-associated
infection in the rabbit tibia caused by Staphylococcus
epidermidis results in lower 18F-FDG uptake than pyo-
genic S. aureus infections [44]. Koort et al. showed that
bone healing is associated with a temporary increase in
18F-FDG uptake, followed by a returned to baseline [28].
In contrast, localized osteomyelitis resulted in a signifi-
cantly higher, continuous uptake of 18F-FDG. Similar
results have been reported in a clinical study [45]. 18F-
FDG PET/CT scanning used for monitoring therapeutic
response to antimicrobials in experimental osteomyelitis
also has been reported. Koort et al. showed the value of
18F-FDG PET for quantitative monitoring of the cipro-
floxacin bone defect filler treatment response in bone in-
fections [25]. Chatziioannou et al. showed the value of
18F-FDG PET for quantitative monitoring of the dapto-
mycin treatment response in infected tibia [43].
Our study has several limitations. Our experiments
were limited to a small number of animals in each
group, and it could be argued that the differences we
observed were even more significant given the small size
of the experimental groups. Additionally, given the lim-
ited volume of the bony cavity, only a single dosage of
vancomycin bead was used. Although this study was not
designed to determine the optimal dosage and duration
of vancomycin for treatment of bone infection, it es-
tablishes a conceptual framework by which to develop
a large animal using dogs or goats. In addition, one
of the inherent limitations of this study is that we do
not know quite well yet how well the results of this
study translate clinically.
In summary, 18F-FDG PET/CT imaging technology is
a sensitive and specific tool in the diagnosis of experi-
mental bon infection and in monitoring the therapeutic
effects of PLGA vancomycin beads. The present study
offers a biodegradable antibiotics bead to meet clinical
requirements for the treatment of bone infection.
Conclusions
Taken together, the in vitro and in vivo results showed
that the use of biodegradable PLGA vancomycin beads
was successful for eradication of the S. aureus pathogen
from bone. These results may have important clinical
applications.
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